Alveolar Dead Space as Predictor of Organ Failure in Severe Sepsis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01315782|
Recruitment Status : Not yet recruiting
First Posted : March 15, 2011
Last Update Posted : May 13, 2016
This is an observational study to understand the changes in alveolar dead space in medical critically ill patients with severe infection (severe sepsis) requiring mechanical ventilation and the possibility to predict multi-organ failure.
The measurement of alveolar dead space used to require sophisticated equipment and time. New ventilators have microprocessors that allow rapid mathematical calculation with minimal intervention.
|Condition or disease|
|Sepsis Severe Sepsis Septic Shock Multi-organ Failure|
The patient will be followed during their ICU stay up to two weeks while on mechanical ventilation.
Patient will be followed daily for the initial 48 hours and then once per week for 2 weeks while mechanically ventilated.
|Study Type :||Observational|
|Estimated Enrollment :||30 participants|
|Official Title:||Alveolar Dead Space as Predictor of Multi-organ Failure and Mortality in Medical Intensive Care Patients With Sepsis Requiring Mechanical Ventilation|
|Study Start Date :||December 2016|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
Alveolar dead space on mechanically ventilated patients with severe sepsis or septic shock.
- Multi-organ failure [ Time Frame: daily for 48 hours then weekly for 2 weeks. ]Multi-oran failure will be accessed by daily laboratory data, heart function by echocardiogram if available, urinary output, vitals and use of vasopressors.
- Mortality [ Time Frame: ICU mortality ]All the patient will be followed up to 28-days to determine survival.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01315782
|Contact: Rosa M Estrada-Y-Martin, MD MScemail@example.com|
|United States, Texas|
|Memorial Hermann Hospital||Recruiting|
|Houston, Texas, United States, 77030|
|Contact: Rosa M Estrada-Y-Martin, MD MSc 713-500-6830 firstname.lastname@example.org|
|Principal Investigator:||Rosa M Estrada-Y-Martin, MD MSc||The University of Texas Health Science Center, Houston|